Pertussis (DBCOND0014696)

Identifiers

Synonyms
Whooping cough due to Bordetella pertussis / Whooping Cough / Whooping cough due to bordetella pertussis (B. pertussis) / Pertussis (disorder)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Ampicillin
A penicillin derivative used for the treatment of a variety of infections caused by gram-positive and gram-negative bacteria as well as some anaerobes.
Bordetella pertussis pertactin antigen (formaldehyde inactivated)
Not Annotated
No drug targets
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus that infects...
No drug targets
Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)
Not Annotated
No drug targets
Clarithromycin
A macrolide antibiotic used for the treatment of a wide variety of bacterial infections such as acute otitis, pharyngitis, tonsillitis, respiratory tract infections, uncomplicated skin infections, and helicobacter pylori infection.
Clostridium tetani toxoid antigen (formaldehyde inactivated)
Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention...
No drug targets
Erythromycin
A macrolide antibiotic used to treat and prevent a variety of bacterial infections.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06618196
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgeNo drug interventionsprevention2not_yet_recruiting
NCT06605755
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old InfantsNo drug interventionspreventionNot Availablerecruiting
NCT01031303
Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Ageprevention4completed
NCT02946190
The PertADO Geneva Trialprevention2completed
NCT03908164
Optimising the Timing of Whooping Cough Immunisation in MUMsNo drug interventionsprevention4unknown_status
NCT00355121
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®prevention2completed
NCT00343421
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlersprevention3completed
NCT00255021
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailandprevention4completed
NCT02301702
Maternal Tdap Immunization in Guatemalaprevention2completed
NCT00619502
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish InfantsNo drug interventionsprevention3completed
NCT01470287
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of AgeNo drug interventionsprevention3completed
NCT01491087
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in Chinaprevention4completed
NCT01597687
Pertussis Infection in Adolescents and Adults With Prolonged CoughNo drug interventionsotherNot Availablecompleted
NCT00534833
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™prevention3completed
NCT02094833
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infantsprevention3completed
NCT02817451
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infantsprevention3completed
NCT00319553
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®prevention4completed
NCT01062477
A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infantsprevention3completed
NCT00255047
Safety and Immune Response of Different Pediatric Combination Vaccines.prevention3completed
NCT00168545
Immunology of Non-specific Effects of Vaccinediagnostic4completed
NCT02257645
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 WeeksNo drug interventionsNot AvailableNot Availableunknown_status
NCT03147898
Observational Study Describing the Immune Profile Induced By Pertussis VaccinesNo drug interventionsNot AvailableNot Availablecompleted
NCT01249183
Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Oldprevention3completed
NCT02458183
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruSNo drug interventionsprevention3completed
NCT03870061
Evaluation of an Infant Immunization Encouragement Program in NigeriaNo drug interventionspreventionNot Availablecompleted
NCT02118961
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescentsprevention3completed
NCT04056728
A Phase IV Study to Assess the Safety of EupentaTM InjNo drug interventionsprevention4unknown_status
NCT02274285
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese InfantsNo drug interventionsprevention3completed
NCT00336115
The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipientsprevention4unknown_status
NCT04102137
3-year Follow-up After a Single Dose Acellular Pertussis VaccinationNot AvailableNot Availablecompleted
NCT00524732
Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of AgeNot AvailableNot Availablecompleted
NCT03982732
Maternal Antibody in Milk After VaccinationNot AvailableNot Availableunknown_status
NCT00319852
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPVprevention3completed
NCT01040052
A Study to Assess the Safety of Adacel® Vaccineprevention3completed
NCT03498300
Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai WomenNo drug interventionsprevention0completed
NCT00712959
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Doseprevention4completed
NCT04073459
Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy InfantsNo drug interventionsprevention2unknown_status
NCT03304275
The Feasibility of Pertussis Immunization in a Canadian Emergency DepartmentNo drug interventionshealth_services_researchNot Availablecompleted
NCT00453570
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Monthsprevention3completed
NCT00432042
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)prevention3completed
NCT06184542
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccineprevention1recruiting
NCT05136599
Establishing a Controlled Human Infection Model of Bordetella Pertussisother1active_not_recruiting
NCT03541499
Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy AdultsNo drug interventionsprevention2completed
NCT00004799
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccinesprevention3completed
NCT00457249
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Olderprevention4completed
NCT02040636
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitisprevention2completed
NCT02382913
Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)Not Available1completed
NCT00467519
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Ageprevention3completed
NCT01706224
Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanish Healthcare ProfessionalsNo drug interventionsNot AvailableNot Availablecompleted
NCT00303316
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infantsprevention3completed
NCT01659996
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Ageprevention4completed
NCT03606096
Gambia Pertussis Study (GaPs)prevention4unknown_status
NCT01267058
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adultsprevention3completed
NCT00347958
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccineprevention4completed
NCT03891758
Confirmatory Study of BK1310 in Healthy Infantsprevention3completed
NCT04694963
A Multi-center Study to Determine the Prevalence and Influence of Pertussis on Subacute Cough in ShenzhenNo drug interventionsNot AvailableNot Availableunknown_status
NCT03931239
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 WeeksNo drug interventionspreventionNot Availablecompleted
NCT00707148
Pertussis Vaccine in Healthy Pregnant Womenprevention1completed
NCT02453048
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis VaccineNo drug interventionsprevention1completed
NCT01311557
Study of Adacel® Vaccine Administered to Persons 10 Years of Ageprevention4completed
NCT00777257
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccineprevention4completed
NCT03909126
Pertussis Vaccination in Pregnant Womenprevention4completed
NCT02408926
Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailandprevention4completed
NCT00304265
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccineNo drug interventionsprevention4completed
NCT04529720
5-year Follow-up After a Single Dose Acellular Pertussis VaccinationNot AvailableNot Availablecompleted
NCT01357720
Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood VaccinationNo drug interventionsprevention4completed
NCT04793620
Pertussis Acellular Vaccine Adjuvanted With TQL1055prevention1terminated
NCT00258882
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ VaccineNot AvailableNot Availablecompleted
NCT00401531
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infantsprevention3completed
NCT03519373
Pertussis Immunization During Pregnancy & HIV InfectionNo drug interventionsNot AvailableNot Availablecompleted
NCT02096276
Boostrix® Pregnancy RegistryNo drug interventionsNot AvailableNot Availablecompleted
NCT01933776
Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in Chinaprevention1completed
NCT06114160
Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning StrategyNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT02526394
Pertussis and Meningitis C Concomitant Vaccination in Adolescentstreatment4completed
NCT00518180
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In AdolescentsNo drug interventionsprevention3completed
NCT01629589
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescentsprevention4completed
NCT00343889
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccineprevention3completed
NCT00287092
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infantsprevention3completed
NCT02858440
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russiaprevention3completed
NCT00802867
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™prevention4completed
NCT00291967
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to InfantsNo drug interventionsprevention2completed
NCT00654901
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™prevention3completed
NCT01233401
Tdap Vaccination for Infant CaregiversNo drug interventionsNot AvailableNot Availablecompleted
NCT00932269
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable DiseaseNo drug interventionsNot AvailableNot Availableunknown_status
NCT04543669
Adacel® Booster Vaccination for CMI Assay Developmentprevention4completed
NCT00254969
Immunogenicity and Safety of Pentaxim in South African Infantsprevention3completed
NCT05457946
Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary SeriesNo drug interventionsprevention2 / 3not_yet_recruiting
NCT00617812
Safety and Immunogenicity Study of a Liquid Pentavalent Combination VaccineNo drug interventionsprevention4completed
NCT01188512
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis VaccineNo drug interventionsprevention1completed
NCT00348881
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy InfantsNo drug interventionsprevention3completed
NCT00258895
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®prevention3completed
NCT00855855
Surveillance Program to Determine Product Specific Rates of Invasive Hib DiseaseNot AvailableNot Availablecompleted
NCT00315055
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Scheduleprevention3completed
NCT00870350
An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine BoosterNo drug interventionsbasic_science4unknown_status
NCT00258908
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwanprevention3completed
NCT00158808
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mthsprevention2completed
NCT00674908
Phase IV Interchangeability Study of a Liquid Pentavalent Combination VaccineNo drug interventionsprevention4completed
NCT01457508
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separatelyprevention3completed
NCT04099303
Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .prevention1completed
NCT00804284
Database Surveillance Safety Study of PENTACEL® VaccineNot AvailableNot Availablecompleted
NCT02759354
Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)No drug interventionsprevention3completed
NCT00404651
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infantsprevention3completed
NCT00831753
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infantsprevention3completed
NCT04779853
Seroprevalence of Pertussis Among Healthy Children and Adolescents in KazakhstanNo drug interventionsNot AvailableNot Availableunknown_status
NCT02089347
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Oldprevention3completed
NCT01890447
Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through ImmunisationNo drug interventionsNot AvailableNot Availablecompleted
NCT00133445
Pentavalent DTaP-Hep B-IPVNo drug interventionsprevention2completed
NCT01529645
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Yearsprevention1completed
NCT01711645
Tdap Vaccine in Post-Partum Womenprevention4completed
NCT03697798
A Study Exploring Whooping Cough Protection in Children and Adultsprevention4completed
NCT04535505
Pathogenic Bordetella Rapid DetectionNo drug interventionsNot AvailableNot Availablewithdrawn
NCT00772928
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™prevention3completed
NCT00831311
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infantsprevention2completed
NCT00797511
Immunogenicity and Safety of Adacel Polio Vaccineprevention3completed
NCT00313911
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.prevention3completed
NCT01346293
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Ageprevention3completed
NCT00013871
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV DrugspreventionNot Availablecompleted
NCT01979588
How Does the Clinical Tool 'What's Going Around' Affect Clinical PracticeNo drug interventionsdiagnosticNot Availablecompleted
NCT06286007
Prevalence and Impact of Pertussis and RSV on Asthma Severity and ControlNo drug interventionsNot AvailableNot Availablerecruiting
NCT00514709
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infantsprevention3completed
NCT04177485
Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, UgandaNo drug interventionspreventionNot Availablecompleted
NCT00259337
Immunogenicity and Safety of Pentaxim™ in an Indian Populationprevention3completed
NCT00004800
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccinesprevention3completed
NCT00514059
Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio VaccineNo drug interventionsprevention4completed
NCT01761799
Protecting Pregnant Women From Infectious DiseasesNo drug interventionshealth_services_researchNot Availablecompleted
NCT03942406
Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adultsprevention2completed
NCT01287949
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Olderprevention3completed
NCT00362336
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPVprevention3completed
NCT02014519
A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in HungaryNo drug interventionsotherNot Availablecompleted
NCT00254917
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippinesprevention4completed
NCT01362517
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type BNo drug interventionstreatment3completed
NCT05193734
Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccinesprevention2 / 3unknown_status
NCT01689324
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescentsprevention1 / 2completed
NCT05856396
Maternal Determinants of Infant Immunity to Pertussisbasic_science4recruiting
NCT05952596
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy AdultsNo drug interventionsprevention1not_yet_recruiting
NCT01137435
Post Marketing Surveillance for ADACEL™ in South Koreaprevention4completed
NCT01878435
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western KenyaNo drug interventionsotherNot Availablecompleted
NCT03950986
Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care SystemNo drug interventionspreventionNot Availablecompleted
NCT00004422
Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis InfectionNo drug interventionstreatment3completed
NCT01984125
Testing the Use of Prompts to Increase Adolescent Immunization RatesNo drug interventionshealth_services_researchNot Availablecompleted
NCT04694430
A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in ShenzhenNo drug interventionsNot AvailableNot Availableunknown_status
NCT00877357
Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination VaccineNo drug interventionsprevention4unknown_status
NCT01917357
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and UnijectNo drug interventionsprevention3completed
NCT01439165
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Doseprevention4completed
NCT00469274
Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis ExposureNo drug interventionspreventionNot Availablecompleted
NCT02587520
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjectsprevention1 / 2completed
NCT01003431
A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)prevention3withdrawn
NCT01993173
Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.prevention3completed
NCT00362427
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®prevention2completed
NCT02511327
Pertussis Immunization During Pregnancy: Effect in Term and Preterm InfantsNo drug interventionsNot AvailableNot Availableunknown_status
NCT02428491
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birthprevention3completed
NCT01129362
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis VaccinesNot AvailableNot Availablecompleted
NCT04023929
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody AssaysNo drug interventionsNot AvailableNot Availableunknown_status
NCT01214889
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.prevention3completed
NCT04618640
To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 YearsNo drug interventionsprevention3unknown_status
NCT03208101
A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy AdultsNo drug interventionsprevention1completed
NCT00138268
Pilot Study Freeze and Transport Immune CellsNo drug interventionsNot AvailableNot Availablecompleted
NCT03589768
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infantsprevention2completed
NCT00092469
Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)prevention3completed
NCT00772369
Retrospective Survey of Safety of Fourth Dose Pentacel® in ChildrenNo drug interventionsNot AvailableNot Availablecompleted
NCT01698346
Pertussis (Tdap) Vaccination in Pregnancyprevention4completed
NCT04589312
Maternal Pertussis Wholecell Responsesprevention2completed
NCT02477995
Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months InfantsNo drug interventionsprevention3completed
NCT01457495
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantlyprevention2completed
NCT03341195
Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in PakistanNo drug interventionspreventionNot Availableunknown_status
NCT03084614
CD8 Reactivity to Microorganisms in Blood and Breast MilkNo drug interventionsNot AvailableNot Availableterminated
NCT04113655
2-year Follow-up After a Single Dose Acellular Pertussis VaccinationNot AvailableNot Availablecompleted
NCT00828555
Effectiveness of a Vaccination Program in the Community Ob/Gyn SettingNo drug interventionsNot AvailableNot Availablecompleted
NCT06056050
A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)No drug interventionsprevention1recruiting
NCT02209623
TDAP Safety in Pregnant WomenNo drug interventionsNot AvailableNot Availablecompleted
NCT01437423
Regulatory Post-Marketing Surveillance Study for TETRAXIM™prevention4completed